Literature DB >> 9684799

Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort.

P A Sakkinen1, M Cushman, B M Psaty, L H Kuller, S P Bajaj, A K Sabharwal, R Boineau, E Macy, R P Tracy.   

Abstract

The majority of fatal acute myocardial infarctions occur in the elderly. Since these events are predominantly thrombotic, we studied the cross-sectional associations of the anticoagulant proteins Antithrombin, Protein C, Protein S. and Tissue Factor Pathway Inhibitor (TFPI) in a subgroup (n = 400) of the Cardiovascular Health Study (a study of healthy men and women > or = 65 years) free of clinical cardiovascular disease (CVD). We did not observe any strong age-associated trends, although Protein C was lower in older women (p < or = 0.001), and TFPI was higher in older men (p < or = 0.01). The inhibitors were highly intercorrelated, and were associated with increased levels of inflammation-sensitive proteins (e.g., fibrinogen. plasminogen), lipids (especially total and LDL-cholesterol), and coagulation factors, such as Factors VIIc, IXc, and Xc. None was associated with the procoagulant markers Prothrombin Fragment F1-2 or Fibrinopeptide A. Only TFPI was associated with subclinical atherosclerosis: ankle-arm index and internal carotid artery stenosis, p trend < or = 0.01; and carotid wall thickness, p trend < or = 0.05. In multivariate analysis the independent predictors of TFPI were levels of fibrinogen; the fibrinolytic marker plasmin-antiplasmin complex; LDL-cholesterol; and carotid wall thickness (R2 for the model = 0.35). In summary, the inhibitors did not appear to increase with age, and were predominantly associated with inflammation markers and lipids. Since markers of thrombin production do increase with age, we hypothesize that an age-related hemostatic imbalance may ensue, with associated increased thrombotic risk. Only TFPI was associated with subclinical CVD, suggesting that it may more closely reflect endothelial damage.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9684799

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

1.  Identification of Genetic Variants Linking Protein C and Lipoprotein Metabolism: The ARIC Study (Atherosclerosis Risk in Communities).

Authors:  James S Pankow; Weihong Tang; Nathan Pankratz; Weihua Guan; Lu-Chen Weng; Mary Cushman; Eric Boerwinkle; Aaron R Folsom
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-01-12       Impact factor: 8.311

2.  Single nucleotide polymorphisms in an intergenic chromosome 2q region associated with tissue factor pathway inhibitor plasma levels and venous thromboembolism.

Authors:  J Dennis; V Truong; D Aïssi; A Medina-Rivera; S Blankenberg; M Germain; M Lemire; L Antounians; M Civelek; R Schnabel; P Wells; M D Wilson; P-E Morange; D-A Trégouët; F Gagnon
Journal:  J Thromb Haemost       Date:  2016-09-17       Impact factor: 5.824

3.  Intra-arterial thrombolysis for acute stroke in patients 80 and older: a comparison of results in patients younger than 80 years.

Authors:  D Kim; G A Ford; C S Kidwell; S Starkman; F Vinuela; G R Duckwiler; R Jahan; J L Saver
Journal:  AJNR Am J Neuroradiol       Date:  2007-01       Impact factor: 3.825

4.  Associations of activated coagulation factor VII and factor VIIa-antithrombin levels with genome-wide polymorphisms and cardiovascular disease risk.

Authors:  N C Olson; L M Raffield; L A Lange; E M Lange; W T Longstreth; G Chauhan; S Debette; S Seshadri; A P Reiner; R P Tracy
Journal:  J Thromb Haemost       Date:  2017-12-08       Impact factor: 5.824

5.  PROC, PROCR and PROS1 polymorphisms, plasma anticoagulant phenotypes, and risk of cardiovascular disease and mortality in older adults: the Cardiovascular Health Study.

Authors:  A P Reiner; C L Carty; N S Jenny; C Nievergelt; M Cushman; D J Stearns-Kurosawa; S Kurosawa; L H Kuller; L A Lange
Journal:  J Thromb Haemost       Date:  2008-08-01       Impact factor: 5.824

Review 6.  Human plasma kallikrein-kinin system: physiological and biochemical parameters.

Authors:  J W Bryant; Z Shariat-Madar
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2009-07

7.  Tissue factor pathway inhibitor, vascular risk factors and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis.

Authors:  C T Mitchell; A Kamineni; W Palmas; M Cushman
Journal:  Atherosclerosis       Date:  2009-04-24       Impact factor: 5.162

8.  Association study to evaluate TFPI gene in CAD in Han Chinese.

Authors:  Ying Zhao; Yanbo Yu; Maowei Shi; Xi Yang; Xueqi Li; Feng Jiang; Yundai Chen; Xiaoli Tian
Journal:  BMC Cardiovasc Disord       Date:  2017-07-17       Impact factor: 2.298

9.  The role of the tissue factor and its inhibitor in the development of subclinical atherosclerosis in people living with HIV.

Authors:  Katarzyna Barska; Wiesława Kwiatkowska; Brygida Knysz; Katarzyna Arczyńska; Maciej Karczewski; Wojciech Witkiewicz
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

10.  Thrombin increases inflammatory cytokine and angiogenic growth factor secretion in human adipose cells in vitro.

Authors:  Jennifer L Strande; Shane A Phillips
Journal:  J Inflamm (Lond)       Date:  2009-03-06       Impact factor: 4.981

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.